Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus tacrolimus in adult first kidney transplant recipients
NL-OMON61082Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of frexalimab in kidney allograft rejection (2 arms), sponsored by Sanofi. Primary endpoint: Composite efficacy failure rate by 1 year. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
frexalimab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON61082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61082.